Friday, 24 June 2022 17:48

Anticoagulation news items. Week commencing 20th June 2022

Venous Thromboembolism Prophylaxis in COVID-19: Making Sense of the Evidence

Annals of Internal Medicine
US article discusses evidence regarding VTE prevention in patients hospitalised with Covid-19, the potential reasons behind the differing outcomes between moderately ill and critically ill patients, and makes suggestions on choice of VTE prophylaxis strategy in these patients.

 

Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis

Circulation
Secondary analysis of the COMPASS trial (27,395) and data review from the VOYAGER PAD study found the vascular benefits of adding rivaroxaban 2.5mg twice daily to aspirin were consistent across age, cancer status number of vascular beds involved and renal function.

 

Time Course for Benefit and Risk With Ticagrelor and Aspirin in Individuals With Acute Ischemic Stroke or Transient Ischemic Attack Who Carry CYP2C19 Loss-of-Function Alleles: A Secondary Analysis of the CHANCE-2 Randomized Clinical Trial

JAMA Neurology
Analysis of 6,412 patients who carry the CYP2C19 loss of function alleles in RCT comparing ticagrelor to clopidogrel (both with aspirin) found a reduction of major ischaemic events with ticagrelor in the first week, which was attenuated in weeks 2 and 3.

 

Subclinical Leaflet Thrombosis and Anticoagulation After Transcatheter Aortic Valve Replacement: A Review

JAMA Cardiology
This narrative review discusses several studies that have investigated the role for oral anticoagulation in patients after transcatheter aortic valve replacement, with a focus on the issue of subclinical leaflet thrombosis.

 

 

The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at:

http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information/new-medicines-awareness-services